Senomyx (NASDAQ: SNMX) and Intrexon (NYSE:XON) are both consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.
This table compares Senomyx and Intrexon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Senomyx and Intrexon, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon has a consensus target price of $34.67, suggesting a potential upside of 121.37%. Given Intrexon’s higher possible upside, analysts plainly believe Intrexon is more favorable than Senomyx.
Volatility and Risk
Senomyx has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Insider & Institutional Ownership
30.2% of Senomyx shares are held by institutional investors. Comparatively, 83.6% of Intrexon shares are held by institutional investors. 13.0% of Senomyx shares are held by company insiders. Comparatively, 48.2% of Intrexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Senomyx and Intrexon’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Senomyx||$29.32 million||2.29||-$1.26 million||($0.03)||-46.33|
|Intrexon||$230.98 million||8.77||-$117.01 million||($0.92)||-17.02|
Senomyx has higher earnings, but lower revenue than Intrexon. Senomyx is trading at a lower price-to-earnings ratio than Intrexon, indicating that it is currently the more affordable of the two stocks.
Senomyx, Inc. discovers, develops, and commercializes flavor ingredients and natural high intensity sweeteners primarily for the packaged food, beverage, and ingredient supply industries in the United States. The company develops and/or commercializes sweet, savory and salt flavor ingredients, bitter blockers and cooling agents. It sells various flavor ingredients directly to flavor companies. The company has collaboration agreements with Ajinomoto Co., Inc.; Firmenich SA; and PepsiCo, Inc. Senomyx, Inc. was founded in 1998 and is headquartered in San Diego, California.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Receive News & Ratings for Senomyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx and related companies with MarketBeat.com's FREE daily email newsletter.